CR11209A - Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta - Google Patents

Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta

Info

Publication number
CR11209A
CR11209A CR11209A CR11209A CR11209A CR 11209 A CR11209 A CR 11209A CR 11209 A CR11209 A CR 11209A CR 11209 A CR11209 A CR 11209A CR 11209 A CR11209 A CR 11209A
Authority
CR
Costa Rica
Prior art keywords
plant
vlps
influenza virus
produced
particles similar
Prior art date
Application number
CR11209A
Other languages
English (en)
Spanish (es)
Inventor
Marc-Andre D'aoust
Manon Couture
Frederic Ors
Sonia Trepanier
Pierre-Olivier Lavoie
Michele Dargis
Louis-Philippe Vezina
Nathalie Landry
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of CR11209A publication Critical patent/CR11209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
    • G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
    • G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
    • G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2209/00—Indexing scheme relating to G06F9/00
    • G06F2209/50—Indexing scheme relating to G06F9/50
    • G06F2209/508—Monitor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Software Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
CR11209A 2007-07-13 2010-01-11 Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta CR11209A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95941407P 2007-07-13 2007-07-13
US99060307P 2007-11-27 2007-11-27
US1327207P 2007-12-12 2007-12-12
CA002615372A CA2615372A1 (en) 2007-07-13 2008-01-21 Influenza virus-like particles (vlps) comprising hemagglutinin
US2277508P 2008-01-22 2008-01-22

Publications (1)

Publication Number Publication Date
CR11209A true CR11209A (es) 2010-03-23

Family

ID=40255124

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11209A CR11209A (es) 2007-07-13 2010-01-11 Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta

Country Status (19)

Country Link
US (4) US20100239610A1 (OSRAM)
EP (1) EP2173886B1 (OSRAM)
JP (1) JP5624465B2 (OSRAM)
KR (1) KR101541330B1 (OSRAM)
CN (1) CN101883856B (OSRAM)
AU (1) AU2008278222B2 (OSRAM)
CA (2) CA2615372A1 (OSRAM)
CR (1) CR11209A (OSRAM)
DK (1) DK2173886T3 (OSRAM)
EA (1) EA018206B1 (OSRAM)
ES (1) ES2428384T3 (OSRAM)
MX (1) MX2010000525A (OSRAM)
MY (1) MY155236A (OSRAM)
NZ (1) NZ582360A (OSRAM)
PL (1) PL2173886T3 (OSRAM)
PT (1) PT2173886E (OSRAM)
SI (1) SI2173886T1 (OSRAM)
TN (1) TN2009000557A1 (OSRAM)
WO (1) WO2009009876A1 (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI377253B (en) 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
US9439959B2 (en) * 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CN103122354B (zh) 2007-11-27 2018-03-23 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
ES2545607T3 (es) 2008-07-08 2015-09-14 Medicago Inc. Antígenos de la gripe recombinantes solubles
CN102149405A (zh) * 2008-07-11 2011-08-10 米迪缪尼股份有限公司 流感血凝素和神经氨酸酶变体
ES2593277T3 (es) * 2008-07-18 2016-12-07 Medicago Inc. Nuevo epítopo de inmunización contra el virus de la influenza
AU2015202195B2 (en) * 2008-07-18 2017-10-12 Medicago Inc. New influenza virus immunizing epitope
KR101939014B1 (ko) 2009-03-16 2019-01-15 디에스엠 아이피 어셋츠 비.브이. 라비린툴로바이코타문 미생물에서의 단백질 생산
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
DK2417153T3 (en) * 2009-04-09 2014-12-01 Alfa Biogene Internat B V Filtration of a liquid comprising a stress protein from a plant
KR101377725B1 (ko) * 2009-06-24 2014-03-27 메디카고 인코포레이티드 헤마글루티닌을 포함하는 키메라 인플루엔자 바이러스-유사 입자
PL222497B1 (pl) 2009-06-26 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania, kompozycja farmaceutyczna oraz zastosowanie wektorowej cząsteczki wirusopodobnej
JP5886194B2 (ja) 2009-07-02 2016-03-16 マサチューセッツ インスティテュート オブ テクノロジー インフルエンザ感染の診断および／または処置のための組成物および方法
BR112012006414B1 (pt) * 2009-09-22 2020-09-15 Medicago Inc Métodos para preparação de proteínas derivadas de plantas
CN103260643A (zh) * 2009-12-28 2013-08-21 梅里亚有限公司 重组ndv抗原及其用途
EP2519636B8 (en) 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
AU2010343095B2 (en) * 2009-12-28 2017-01-05 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
AU2015202267B2 (en) * 2010-01-26 2017-03-23 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
BR112013007593A2 (pt) 2010-09-30 2016-08-09 Franvax S R L partícula de virossoma produzida sinteticamente, vacina, método para produzir uma partícula de virossoma, uso de uma partícula de virossoma e de uma vacina
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
KR20130122947A (ko) * 2010-10-27 2013-11-11 필립모리스 프로덕츠 에스.에이. 팽창성 베드 크로마토그래피를 사용하여 식물로부터 바이러스 유사 입자를 포획하는 방법
CN103282501A (zh) 2010-11-04 2013-09-04 麦迪卡格公司 植物表达系统
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
US20140059718A1 (en) * 2011-01-17 2014-02-27 Philip Morris Products S.A. Vectors for nucleic acid expression in plants
TWI620816B (zh) * 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
ES2665512T3 (es) * 2011-06-13 2018-04-26 Medicago Inc. Producción de partículas pseudovíricas de la rabia en plantas
AU2012273039B2 (en) 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
DK2760882T5 (da) 2011-09-30 2024-06-24 Medicago Inc Forøgelse af udbyttet af viruslignende partikler i planter
WO2013068593A1 (en) * 2011-11-11 2013-05-16 Philip Morris Products S.A. Influenza virus -like particles (vlps) comprising hemagglutinin produced nicotiana tabacum
BR112014018884A2 (pt) 2012-02-07 2017-07-04 Univ Pittsburgh Commonwealth Sys Higher Education antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
MX359071B (es) 2012-02-13 2018-09-13 Univ Pittsburgh Commonwealth Sys Higher Education Antígenos ampliamente reactivos computacionalmente optimizados para influenza h5n1 humana y aviar.
EP2827893B1 (en) 2012-03-22 2017-11-29 Fraunhofer USA, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
KR102162118B1 (ko) * 2012-05-11 2020-10-07 메디카고 인코포레이티드 식물에서 로타바이러스-유사 입자 생산
SG11201501523XA (en) * 2012-09-05 2015-03-30 Medicago Inc Picornavirus-like particle production in plants
CN105263516A (zh) 2012-12-18 2016-01-20 西奈山伊坎医学院 流感病毒疫苗及其用途
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
ES2803508T3 (es) 2013-03-28 2021-01-27 Medicago Inc Producción de partículas similares al virus de la gripe en plantas
WO2015034042A1 (ja) 2013-09-06 2015-03-12 三菱化学株式会社 植物を用いたタンパク質の製造方法
ES2912291T3 (es) 2014-03-27 2022-05-25 Medicago Inc Elementos potenciadores de CPMV modificados
EP3167057B1 (en) * 2014-07-11 2020-03-25 Medicago Inc. Modifying protein production in plants
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JP6841762B2 (ja) 2015-01-23 2021-03-10 メディカゴ インコーポレイテッド 植物中でのロタウイルス様粒子産生
KR101637955B1 (ko) * 2015-05-18 2016-07-08 한국생명공학연구원 범용성 인플루엔자 바이러스 백신 조성물
EP3316677B1 (en) 2015-07-02 2021-02-17 Medicago Inc. Jasmonic acid pathway activator
BR112018075032A2 (pt) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai proteínas de hemaglutinina do vírus influenza e seus uso
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
KR101964044B1 (ko) * 2018-03-14 2019-04-02 인제대학교 산학협력단 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼
AU2019233860B2 (en) 2018-03-14 2025-02-13 Aramis Biotechnologies Inc. Plant expression enhancer
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3103840A1 (en) * 2018-06-27 2020-01-02 Medicago Inc. Influenza virus hemagglutinin mutants
CN112384615A (zh) 2018-07-04 2021-02-19 普罗拜奥根股份公司 用于纯化包膜病毒的方法
BR112021017899A2 (pt) 2019-03-14 2021-12-21 Medicago Inc Intensificador de expressão vegetal endógeno
WO2021002355A1 (ja) 2019-07-03 2021-01-07 アイリス株式会社 インフルエンザウイルス感染症を治療するための医薬組成物
CN111122417B (zh) * 2020-02-22 2022-06-21 太原理工大学 一种测定含瓦斯煤开闭孔总体积膨胀率的装置及方法
EP4351320A1 (en) 2021-06-09 2024-04-17 ImmunityBio, Inc. Methods and systems for producing a protein of interest in a plant
CN115992101B (zh) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 一种流感病毒裂解疫苗原液的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003224A1 (en) 1984-11-29 1986-06-05 Scripps Clinic And Research Foundation Polypeptides and antibodies related to deglycosylated viral glycoproteins
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
EP0509656B1 (en) * 1991-03-28 1996-09-18 Rooperol (Na) Nv Compositions of phytosterols and phytosterolins as immunmodulators
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
AU6504796A (en) 1995-07-20 1997-02-18 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
KR20010072372A (ko) 1998-08-11 2001-07-31 맥기 데이비드 알 식물조직의 간질액으로부터 단백질을 추출하는 방법
WO2000020557A2 (en) 1998-10-07 2000-04-13 Boyce Institute For Plant Research At Cornell University Gemini virus vectors for gene expression in plants
US6287570B1 (en) * 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
HUP0300187A3 (en) 1999-04-29 2004-11-29 Syngenta Ltd Haslemere Herbicide resistant plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE433491T1 (de) 2001-01-18 2009-06-15 Vlaams Interuniv Inst Biotech Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
CN1333370A (zh) * 2001-08-16 2002-01-30 深圳市三方圆信息技术有限公司 抗家禽病毒病的作物及其生产方法
JP4430942B2 (ja) 2002-02-13 2010-03-10 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション インフルエンザウイルスベクターのパッケージングのためのシグナル
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
CN1665934B (zh) * 2002-03-19 2010-05-26 国际植物研究所 GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
CU23202A1 (es) * 2003-01-31 2007-05-18 Ct Ingenieria Genetica Biotech ANTIGENOS RECOMBINANTES DEL VIRUS DE LA HEPATITIS A OBTENIDOS EN CéLULAS VEGETALES
CN1460718A (zh) * 2003-04-11 2003-12-10 浙江大学 表达传染性支气管炎病毒纤突蛋白的转基因马铃薯生产方法
CN101123871B (zh) 2003-05-05 2011-05-18 美国陶氏益农公司 来源于转基因植物细胞的稳定免疫预防性和治疗性组合物及其制备方法
AU2004235813B2 (en) * 2003-05-05 2010-07-29 Boyce Thompson Institute For Plant Research Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP3388521A1 (en) * 2004-02-27 2018-10-17 Dow AgroSciences LLC High efficiency peptide production in plant cells
US7901691B2 (en) 2004-08-13 2011-03-08 Council Of Scientific And Indistrial Research Chimeric G protein based rabies vaccine
EP1883701B1 (en) 2005-04-29 2012-01-18 University of Cape Town Expression of viral proteins in plants
CN100410378C (zh) 2005-05-09 2008-08-13 中国农业科学院生物技术研究所 编码禽流感血凝素的基因及其植物表达载体和应用
CA2615658A1 (en) 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
EP1945250A4 (en) 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE AGAINST INFLUENZA
RU2483751C2 (ru) * 2005-10-18 2013-06-10 Новавакс, Инк. ФУНКЦИОНАЛЬНЫЕ ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ ГРИППА (VLPs)
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
WO2008060669A2 (en) 2006-04-21 2008-05-22 Dow Agrosciences Llc Vaccine for avian influenza and methods of use
BRPI0707733B1 (pt) 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
WO2007130327A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Influenza virus-like particle (vlp) compositions
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
EP2155880B1 (en) 2007-06-15 2016-08-10 Medicago Inc. Modifying glycoprotein production in plants
KR100964462B1 (ko) 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
CA2696764A1 (en) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
CN103122354B (zh) 2007-11-27 2018-03-23 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
WO2009083420A1 (en) 2007-12-28 2009-07-09 Unilever Plc Process for recovering aroma from tea
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
ES2545607T3 (es) 2008-07-08 2015-09-14 Medicago Inc. Antígenos de la gripe recombinantes solubles
ES2593277T3 (es) 2008-07-18 2016-12-07 Medicago Inc. Nuevo epítopo de inmunización contra el virus de la influenza
AU2009285667B2 (en) 2008-08-27 2015-05-28 Arizona Board Of Regents For And On Behalf Of Arizona State University A DNA replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
US8283368B2 (en) 2008-08-29 2012-10-09 The Regents Of The University Of Michigan Selective ligands for the dopamine 3 (D3) receptor and methods of using the same
WO2010077712A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Bovine respiratory syncytial virus virus-like particle (vlps)
KR101377725B1 (ko) * 2009-06-24 2014-03-27 메디카고 인코포레이티드 헤마글루티닌을 포함하는 키메라 인플루엔자 바이러스-유사 입자
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
BR112012006414B1 (pt) 2009-09-22 2020-09-15 Medicago Inc Métodos para preparação de proteínas derivadas de plantas
WO2011102900A1 (en) 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines
CN103282501A (zh) 2010-11-04 2013-09-04 麦迪卡格公司 植物表达系统
EP3246019B1 (en) 2010-11-05 2021-03-03 Novavax, Inc. Rabies glycoprotein virus-like particles (vlps)
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp

Also Published As

Publication number Publication date
US20130183341A1 (en) 2013-07-18
WO2009009876A1 (en) 2009-01-22
CA2615372A1 (en) 2009-01-13
TN2009000557A1 (en) 2011-03-31
NZ582360A (en) 2012-04-27
EA018206B1 (ru) 2013-06-28
MY155236A (en) 2015-09-30
SI2173886T1 (sl) 2013-11-29
EA201000195A1 (ru) 2010-10-29
JP5624465B2 (ja) 2014-11-12
CN101883856A (zh) 2010-11-10
JP2010533001A (ja) 2010-10-21
CA2693956C (en) 2013-09-24
DK2173886T3 (da) 2013-09-30
EP2173886B1 (en) 2013-06-26
MX2010000525A (es) 2010-04-27
AU2008278222B2 (en) 2014-03-06
CA2693956A1 (en) 2009-01-22
US9492528B2 (en) 2016-11-15
US9452210B2 (en) 2016-09-27
KR101541330B1 (ko) 2015-08-05
US20230044454A1 (en) 2023-02-09
US20100239610A1 (en) 2010-09-23
EP2173886A1 (en) 2010-04-14
ES2428384T3 (es) 2013-11-07
PL2173886T3 (pl) 2013-12-31
EP2173886A4 (en) 2010-10-13
PT2173886E (pt) 2013-09-03
CN101883856B (zh) 2013-10-30
US20110293650A1 (en) 2011-12-01
AU2008278222A1 (en) 2009-01-22
KR20100032920A (ko) 2010-03-26

Similar Documents

Publication Publication Date Title
CR11209A (es) Particulas similares al virus de la influenza (vlps) que comprenden hemaglutinina producida dentro de una planta
CR11612A (es) Particulas tipo virus de influenza recombinante (vlp) producidas en plantas transgenicas que expresan hemaglutinina
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
WO2010003225A8 (en) Influenza virus-like particles (vlps) comprising hemagglutinin
MX373717B (es) Composiciones concentradas para la limpieza personal y metodos.
UY32717A (es) Inhibidores de la replicación de virus de la gripe
CL2012002419A1 (es) Metodo para mejorar una caracteristica de una planta que comprende administrar bacillus subtilis fb17 a la planta, semilla o al suelo alrededor de la planta o semilla; y metodo para producir biocombustible.
UY36334A (es) Composiciones de bacillus licheniformis rt1184 y metodos de usos para beneficiar el crecimiento de las plantas
MX392185B (es) Metodo de uso de una composicion que comprende un compuesto de amonio cuaternario, un polisacarido cationico y un polisacarido no ionico.
MY161965A (en) New influenza virus immunizing epitope
MX2015013700A (es) Produccion de particulas similares a virus de influenza en plantas.
CL2007000525A1 (es) Método para aumentar el rendimiento de semillas de plantas que consiste en aumentar la expresión de una secuencia de ácido nucleico que codifica un dominio del factor de transcripción del polipéptido myb; método de producción de planta transgénica; y uso de la secuencia de ácido nucleico para aumentar el rendimiento de semillas de plantas.
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
CL2008001294A1 (es) Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua.
CL2015000968A1 (es) Método de promoción del crecimiento de una planta que comprende la aplicación de un compuesto derivado de carboxamida; y uso de dicho compuesto.
BR112016017612A2 (pt) Uso de um extrato de uma planta do gênero mentha da família lamiaceae
CL2012002370A1 (es) Metodo para incrementar el uso eficiente de nitrogeno de una planta en relacion a una planta de tipo natural o no transformada de la misma especie a traves de la modulacion de la expresion omega amidasa.
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
AR069187A1 (es) Metodo, uso y agente para proteger una planta contra phakopsora
CO6781543A2 (es) Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie
AR060182A1 (es) Polisacaridos capsulares tipo 5 y tipo 8 de cepas s. aureus de sobreproduccion
CL2008003154A1 (es) Proceso de obtencion de un extracto estandarizado de aleuterites moluccana; extracto estandarizado de aleurites moluccana; composicion farmaceutica que comprende el extracto; uso del extracto para tratar condiciones de dolor.
CL2008001066A1 (es) Uso de un extracto de una planta de vernonia de madagascar para mejorar el estado de la piel.
CL2014000140A1 (es) Uso de anolito neutro para descontaminar troncos de vid; procedimiento para producir planta de vid injerto-soldada que comprende aplicar dicho anolito neutro.
BR112018013754A2 (pt) recuperação fitoquímica a partir de plantas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)